655. Analysis of Microbiome Diversity and Secondary Bile Acid Synthesis Following SER-109 or Placebo in Patients with First Recurrent or Multiply Recurrent Clostridioides difficile Infection

BACKGROUND: Treatment for first recurrent Clostridioides difficile infection (frCDI) or multiply recurrent CDI (mrCDI) is complex and may include antibiotics, monoclonal antibodies, or fecal transplantation. Improved understanding of rCDI pathogenesis can help guide treatment. We report microbiome f...

Descripción completa

Detalles Bibliográficos
Autores principales: Kelly, Colleen R, Kraft, Colleen S, Straub, Tim, Litcofsky, Kevin, Wortman, Jennifer R, Cohen, Stuart H, Berenson, Charles, McGovern, Barbara, Hasson, Brooke, Hot, Dina, Pardi, Darrell, Ford, Christopher, Henn, Matthew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679316/
http://dx.doi.org/10.1093/ofid/ofad500.718

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679316/
http://dx.doi.org/10.1093/ofid/ofad500.718

Ejemplares similares